Soleus Capital Management, L.P. 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Soleus Capital Management, L.P. disclosed 94 US equity positions worth $2.4bn in its Q4 2025 13F filing. The largest position was KRYS at 9.8% of the reported book, followed by CELC and NVCR. Against the Q3 2025 filing, it opened 13 new positions, added to 20 and reduced 14 among the top 50 holdings.
What did Soleus Capital Management, L.P. own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | KRYS KRYSTAL BIOTECH INC | Healthcare | 9.8% | $232.0m | 941,059 | -8% | reduced |
| 2 | CELC CELCUITY INC | Healthcare | 7.7% | $180.4m | 1,808,258 | 53% | added |
| 3 | NVCR NOVOCURE LTD | Healthcare | 4.7% | $110.3m | 8,530,665 | -12% | reduced |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 4.5% | $107.0m | 362,966 | -58% | reduced |
| 5 | TGTX TG THERAPEUTICS INC | Healthcare | 4.0% | $93.6m | 3,139,312 | -18% | reduced |
| 6 | DXCM DEXCOM INC | Healthcare | 3.7% | $86.1m | 1,297,094 | – | new |
| 7 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.3% | $78.4m | 1,320,000 | 48% | added |
| 8 | GMED GLOBUS MED INC | Healthcare | 3.3% | $77.4m | 887,000 | 404% | added |
| 9 | BBNX BETA BIONICS INC | Healthcare | 3.3% | $77.2m | 2,534,565 | -35% | reduced |
| 10 | AM6 AMICUS THERAPEUTICS INC | 3.1% | $74.2m | 5,207,284 | 11% | added | |
| 11 | TWST TWIST BIOSCIENCE CORP | Healthcare | 2.5% | $59.1m | 1,861,802 | -0% | held |
| 12 | ORGO ORGANOGENESIS HLDGS INC | Healthcare | 2.2% | $51.7m | 9,985,951 | -18% | reduced |
| 13 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.0% | $47.2m | 2,247,110 | 12% | added |
| 14 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.9% | $45.3m | 573,614 | 286% | added |
| 15 | PODD INSULET CORP | Healthcare | 1.8% | $42.6m | 150,000 | – | new |
| 16 | NPCE NEUROPACE INC | 1.8% | $41.7m | 2,703,208 | -9% | reduced | |
| 17 | AXGN AXOGEN INC | Healthcare | 1.7% | $39.5m | 1,206,855 | -30% | reduced |
| 18 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 1.6% | $38.4m | 486,243 | 43% | added |
| 19 | ALKS ALKERMES PLC | Healthcare | 1.6% | $37.0m | 1,322,364 | – | new |
| 20 | LIVN LIVANOVA PLC | Healthcare | 1.5% | $34.9m | 567,500 | – | new |
| 21 | GSK GSK PLC | Healthcare | 1.3% | $31.3m | 639,000 | 190% | added |
| 22 | GERN GERON CORP | Healthcare | 1.3% | $30.7m | 23,290,000 | 35% | added |
| 23 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.2% | $29.2m | 60,000 | -60% | reduced |
| 24 | IMVT IMMUNOVANT INC | Healthcare | 1.2% | $28.2m | 1,110,000 | – | new |
| 25 | PCVX VAXCYTE INC | Healthcare | 1.2% | $28.1m | 608,958 | – | new |
| 26 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.2% | $27.8m | 70,000 | 359% | added |
| 27 | INSP INSPIRE MED SYS INC | Healthcare | 1.2% | $27.6m | 299,399 | -59% | reduced |
| 28 | VCEL VERICEL CORP | Healthcare | 1.2% | $27.5m | 764,000 | 53% | added |
| 29 | ARGX ARGENX SE | Healthcare | 1.1% | $26.7m | 31,726 | -54% | reduced |
| 30 | RAPT RAPT THERAPEUTICS INC | 1.1% | $25.9m | 764,000 | 42% | added | |
| 31 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.1% | $25.0m | 175,982 | 28% | added |
| 32 | KINIKSA PHARMACEUTICALS INTL | 1.0% | $24.2m | 587,000 | 291% | added | |
| 33 | EDAP TMS S A | 1.0% | $24.0m | 7,309,254 | 0% | held | |
| 34 | TFX TELEFLEX INCORPORATED | Healthcare | 1.0% | $23.2m | 190,000 | – | new |
| 35 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.0% | $23.1m | 1,219,394 | -50% | reduced |
| 36 | EWTX EDGEWISE THERAPEUTICS INC | 1.0% | $22.6m | 910,000 | – | new | |
| 37 | IKT INHIBIKASE THERAPEUTICS INC | 0.9% | $22.3m | 10,875,000 | 72% | added | |
| 38 | PHVS PHARVARIS N V | 0.8% | $19.5m | 702,052 | 9% | added | |
| 39 | IVVD INVIVYD INC | Healthcare | 0.8% | $19.0m | 7,708,727 | – | new |
| 40 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 0.8% | $18.7m | 646,390 | – | new |
| 41 | THC TENET HEALTHCARE CORP | Healthcare | 0.8% | $18.4m | 92,500 | – | new |
| 42 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.7% | $17.0m | 711,983 | – | new |
| 43 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.7% | $15.8m | 1,025,000 | – | new |
| 44 | MBX MBX BIOSCIENCES INC | Healthcare | 0.5% | $12.9m | 408,900 | 49% | added |
| 45 | RIGL RIGEL PHARMACEUTICALS INC | 0.5% | $12.9m | 300,034 | -9% | reduced | |
| 46 | JBIO JADE BIOSCIENCES INC | 0.5% | $12.3m | 796,744 | 0% | held | |
| 47 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.5% | $11.3m | 900,000 | 3500% | added |
| 48 | SION SIONNA THERAPEUTICS INC | 0.5% | $11.0m | 268,500 | -35% | reduced | |
| 49 | SEPN SEPTERNA INC | 0.5% | $10.7m | 383,368 | 1999% | added | |
| 50 | KIDS ORTHOPEDIATRICS CORP | Healthcare | 0.4% | $9.3m | 525,447 | 311% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.